Gentamicins are clinically valuable aminoglycoside antibiotics isolated as gentamicin C complex, a mixture of five components ([Fig. 1](#fig01){ref-type="fig"}), from the filamentous bacterium *Micromonospora echinospora*. Gentamicins are protein synthesis inhibitors used to combat Gram-negative bacterial infections. They are also being actively explored for use in other applications ([@r1][@r2]--[@r3]). However, gentamicins carry a serious risk of kidney damage and irreversible hearing loss ([@r4], [@r5]), which limits their utility. Encouragingly, individual components of the gentamicin mixture may have lower toxicity ([@r6], [@r7]). Individual components of gentamicin C can already be separated after manual chemical derivatization ([@r8]), but achieving this by low-cost direct fermentation would significantly advance interest in single components both as starting material for semisynthesis to novel gentamicins and for testing as therapeutics in their own right.

![Methyltransfer reactions in gentamicin biosynthetic pathway. The determined major and minor alternative pathways in the methylation network are indicated by boldface type and solid arrows, respectively. The dashed arrows refer to conversions without substantial experimental support. Methyltransferases and their roles revealed in this study of GenN, GenD1, GenK, and GenL are highlighted in magenta, orange, blue, and red, respectively. The extents of methylation are shown in the dashed rectangle boxes. Carbon numbering is shown with the structure of **1**.](pnas.1711603115fig01){#fig01}

Gentamicins are modified sugars containing an unusual aminocyclitol ring (2-deoxystreptamine, 2-DOS) ([@r9], [@r10]). The enzymatic steps that lead to the 2-DOS scaffold, and thence to the pseudodisaccharide paromamine ([@r11][@r12]--[@r13]) and the pseudotrisaccharide gentamicin A2 (**1**) ([@r14]) ([Fig. 1](#fig01){ref-type="fig"}), have all been elucidated, and more recently rapid progress has also been made in delineating the later steps of gentamicin biosynthesis, greatly aided by the sequencing of the gentamicin biosynthetic gene cluster ([@r15][@r16]--[@r17]) and the related sisomicin cluster ([@r18]). We have previously used a combination of genetic and biochemical evidence to reveal that, starting from the intermediate 3″-dehydro-3″-oxo-gentamicin A2 (DAA2) (**2**) ([Fig. 1](#fig01){ref-type="fig"}), the *S*-adenosylmethionine (SAM)-dependent methyltransferase GenN catalyzes 3′′-*N*-methylation, followed by 4″-*C*-methylation catalyzed by a cobalamin- and radical SAM-dependent methyltransferase GenD1, to form gentamicin X2 (**4**) ([@r19]). In the same way, we ([@r20]) and others ([@r21][@r22][@r23]--[@r24]) have shown that a second cobalamin- and radical SAM-dependent methyltransferase, GenK, catalyzes 6′-*C*-methylation of gentamicin X2 (**4**) to initiate the branch of the gentamicin pathway that leads via G418 (**5**) to gentamicin components C2a, C2, and C1. The full mechanistic details of the subsequent transamination and dehydroxylation steps remain to be clarified, although the dehydrogenase GenQ ([@r20]), phosphotransferase GenP, and the pyridoxal-dependent enzymes GenB1, GenB2, GenB3, and GenB4 have all been implicated in this enigmatic process ([@r20], [@r25], [@r26]). Finally, the terminal step in both branches of the pathway involves the (partial) conversion of C1a into C2b and of C2 into C1, catalyzed by an unidentified 6′-*N*-methyltransferase (or possibly two different methyltransferases). Given the decisive role of methylation in shaping the pathway to the gentamicin C complex, we have used mutant strains of *M. echinospora* engineered to contain different complements of GenN, GenD1, and GenK to investigate the substrate selectivity of these known methyltransferases to determine the scope for altering the methylation pattern; and we have tracked down and identified, by combined biochemical and genetic approaches, the terminal methyltransferase (named GenL). GenL is located on its own 2.54 Mbp from the previously characterized gentamicin gene cluster. We show that GenL is necessary and sufficient to catalyze the 6′-*N*-methylation of both C2 and C1a. It follows that future judicious manipulation of the levels of (in particular) GenK and GenL activity in cells should permit targeted enrichment of individual components of the gentamicin C complex.

Results {#s1}
=======

Systematic Deletion of One or More of the Methyltransferase Genes *genN*, *genD1*, and *genK* Reveals Alternative Minor Pathways for Methylation. {#s2}
-------------------------------------------------------------------------------------------------------------------------------------------------

Commercial samples of gentamicin C complex obtained by fermentation contain variable amounts of minor gentamicin metabolites as impurities. Careful analysis has detected as many as 21 such minor products in a single sample ([@r27]). For 6 of these, the structure could be determined by MS and MS^n^ methods, and structures could also be proposed for 13 others ([@r27]). In previous work it has been shown that levels of certain metabolites with altered methylation patterns are enhanced upon deletion of either *genN* ([@r19], [@r28]) or *genK* ([@r20]). We therefore set out systematically to alter the complement of known methyltransferase genes and to study the metabolites produced.

First, the single mutants of *genN* and *genD1*, which were constructed in our previous studies ([@r19], [@r20]), were used to generate the series of mutants ΔgenD1ΔgenN, ΔgenD1ΔgenK, ΔgenNΔgenK, and ΔgenD1ΔgenKΔgenN. In these mutants, an internal fragment has been deleted in-frame, respectively, from *genN*, *genD1*, and *genK*. These mutants were confirmed by PCR and Southern blotting and then fermented ([*SI Appendix*, Fig. S1 *A*--*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). The extracts were analyzed by using liquid chromatography coupled with electrospray ionization high-resolution mass spectrometry (LC-ESI-HRMS) and tandem mass spectrometry (MS/MS).

The triple-mutant ΔgenD1ΔgenKΔgenN produced small amounts of **2** ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Figs. S2*A* and S3*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) ([@r19]), the upstream precursor of gentamicin A (**3**) ([Figs. 1](#fig01){ref-type="fig"} and [2*A*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S2*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). NMR data confirmed the structure of **2** as a nonmethylated species as previously proposed ([*SI Appendix*, Fig. S3*A* and Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). The intermediate **1** ([Figs. 1](#fig01){ref-type="fig"} and [2*A*](#fig02){ref-type="fig"}) was present as the major species, but no other gentamicin-related metabolite was present. The ΔgenD1ΔgenK mutant produced **1** and **3** ([Figs. 1](#fig01){ref-type="fig"} and [2*B*](#fig02){ref-type="fig"}), but no other methylated intermediates or other gentamicins. These results confirm that GenN is essential for the methylation on 3′′-*N* of **2**. In extracts of the ΔgenNΔgenK mutant, intermediates **1** and **2** were detected at levels similar to those in the triple mutant, but an additional compound with the same molecular mass as **3** was observed, singly methylated on 3′′-*N* ([Figs. 1](#fig01){ref-type="fig"} and [2*C*](#fig02){ref-type="fig"}). Given the known regiospecificity of GenD1 ([@r19]), the site of modification is proposed to be at C-4′′ ([*SI Appendix*, Fig. S2*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). This metabolite, named here gentamicin A-1 (**6**) ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S2*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)), has been described as a trace component of a wild-type fermentation ([@r27]). In the extract of the ΔgenD1ΔgenN mutant, **2** was detected at levels similar to those in the triple mutant along with two 6′-*C*-methylated metabolites ([Fig. 2*D*](#fig02){ref-type="fig"}). One of these is formed as a result of the precocious action of GenK on **2** and is named here gentamicin A-2 (**7**) ([Figs. 1](#fig01){ref-type="fig"} and [2*D*](#fig02){ref-type="fig"} and [*SI Appendix*, Figs. S2*D* and S3*B* and Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). It is assumed to have the same relative configuration at C-6′ as **5** ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S2*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) and has also been previously described as a trace component of a wild-type fermentation ([@r26]). The second metabolite A2e (**8**) ([Figs. 1](#fig01){ref-type="fig"} and [2*D*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S2*F*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) is formed by the known precocious action of GenK on **1** ([@r19], [@r24]).

![LC-ESI-HRMS analysis of gentamicin-related intermediates from mutant strains. Extracted ion chromatogram of intermediates in (*A*) ΔgenD1ΔgenKΔgenN, (*B*) ΔgenD1ΔgenK, (*C*) ΔgenNΔgenK, (*D*) ΔgenD1ΔgenN, (*E*) ΔgenK, (*F*) ΔgenD1, and (*G*) ΔgenN.](pnas.1711603115fig02){#fig02}

We repeated our previous analysis of the ΔgenN, ΔgenD1 and ΔgenK mutants ([@r19], [@r20]) and scrutinized the extracts carefully for metabolites with an altered methylation pattern. The ΔgenK mutant produced **3** and **4** ([*SI Appendix*, Fig. S2*G*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) as expected but only a trace of the metabolite we have assigned as **6** ([Figs. 1](#fig01){ref-type="fig"} and [2*E*](#fig02){ref-type="fig"}), confirming that GenD1 fails to compete successfully with GenN for methylation of **2**. The ΔgenD1 mutant in contrast produced a relatively large amount of the known doubly methylated metabolite gentamicin Ae (**9**) ([Figs. 1](#fig01){ref-type="fig"} and [2*F*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S2*H*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) ([@r19], [@r27]), again a consequence of the precocious action of GenK. We confirmed the structure of **9** by NMR ([*SI Appendix*, Fig. S3*C* and Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). The ΔgenN mutant produced low levels of **2**, but mainly produced **1**, as well as the singly methylated species **6**, **7**, **8**, and an intermediate with the same molecular mass and MS/MS fragmentation as **9**, which we name here gentamicin X2-1 (**10**) ([Figs. 1](#fig01){ref-type="fig"} and [2*G*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S2*I*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). This compound, which has also been described as a trace component of wild-type gentamicin fermentation ([@r27]), is most likely methylated at both C-4″ and C-6′ positions. Another compound with the same molecular mass and MS/MS fragmentation as **10** was also observed, named here X2-1-i, which may be an isomer of it ([Fig. 2*G*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S2*I*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). These species with various methylation patterns suggest a metabolic network in the pathway, in which methylations at the three sites occur relatively independently of each other rather than in a strictly fixed order.

Bioconversion in Vivo and in Vitro of Gentamicin Metabolites Confirms the Selectivity of Methylation by GenN, GenD1, and GenK. {#s3}
------------------------------------------------------------------------------------------------------------------------------

Established gentamicin intermediates **2**, **3**, and **4** as well as gentamicin metabolites with altered methylation patterns **6**, **7**, **9,** and **10** were isolated from the mutants described above, as described in [*Materials and Methods*](#s7){ref-type="sec"} ([*SI Appendix*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). We aimed to interrogate directly the ability of individual methyltransferases to use these compounds as substrates and verify which of the possible conversions in the methylation network actually occur. To do this, the gentamicin biosynthetic gene cluster (GenBank accession no. KY971520) from *grmB* to *genN* was knocked out by deletion of a 40,524-bp fragment to generate the ΔBN mutant, which was confirmed by PCR and Southern blotting analysis ([*SI Appendix*, Fig. S1*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). Complementation of the ΔBN mutant by using plasmid pWHU91 ([*SI Appendix*, Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) containing *genN* and *gmrA* under the control of the P*ermE\** promoter, respectively, generated ΔBN::*gmrA*+*genN* ([*SI Appendix*, Fig. S5*B* and Table S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). In parallel, ΔBN::*gmrA*+*genD1* and ΔBN::*gmrA*+*genK* were constructed in the same way with pWHU92 and pWHU93 ([*SI Appendix*, Figs. S5 *C* and *D*, and Table S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). The gene *gmrA* that confers gentamicin self-resistance was present to avoid toxicity of gentamicin metabolites in the host strain. The strain ΔBN::*gmrA* was constructed as a negative control by using pWHU90 ([*SI Appendix*, Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)), which contains *gmrA* only, under the control of the constitutive P*ermE\** promoter ([*SI Appendix*, Fig. S5*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)).

The results from LC-ESI-HRMS and MS/MS showed that feeding either **2**, **3** (the normal substrate), **7,** or **9** to ΔBN::*gmrA*+*genD1* led to detectable methylation, which is presumed to be at C-4″ ([Fig. 3*A*](#fig03){ref-type="fig"}). Likewise, feeding **2**, **3,** or **4** (the normal substrate) to ΔBN::*gmrA*+*genK* in each case led to detectable methylation (presumed to be at C-6′) ([Fig. 3*B*](#fig03){ref-type="fig"}). In contrast, feeding of **6** to this strain did not produce **10**. Meanwhile, feeding of **2** (the normal substrate) to ΔBN::*gmrA*+*genN* generated **3**, and feeding of **7** to this strain generated **9** ([Fig. 3*C*](#fig03){ref-type="fig"}). However, neither **6** nor **10** were methylated in this strain.

![Production of gentamicin intermediates in feeding experiments. Extracted ion chromatograms are shown from LC-ESI-HRMS of feeding experiments: (*A*) ΔBN::*gmrA*+*genD1* fed with **2**, **3**, **7,** and **9**, respectively. (*B*) ΔBN::*gmrA*+*genK* fed with **2**, **3,** and **4**, respectively. (*C*) ΔBN::*gmrA*+*genN* fed with **2** and **7**, respectively. Host refers to ΔBN::*gmrA*.](pnas.1711603115fig03){#fig03}

Consistent with the in vivo biotransformation results, purified His-tagged recombinant GenN catalyzed methylation of **2** and **7** into **3** and **9**, respectively, with SAM as a methyl donor ([Fig. 4](#fig04){ref-type="fig"}). No methylated product was observed when **6** and **10** were used as substrates under the same assay conditions.

![LC-ESI-MS analysis of in vitro activities of GenN on gentamicin intermediates **2** and **7**. In the presence of SAM, GenN catalyzed methylation of (*A*) **2** to **3** and (*B*) **7** to **9**, respectively. The extracted ion traces of substrates are in gray and those of the products are in black.](pnas.1711603115fig04){#fig04}

The Enzyme GenL, Required for the Terminal 6′-*N*-Methylation Step in Both Branches of the Gentamicin Biosynthetic Pathway, Has Been Identified. {#s4}
------------------------------------------------------------------------------------------------------------------------------------------------

Preliminary experiments showed that C2 was readily bioconverted into C1 when fed to *M. echinospora* ΔBN::*gmrA*, which lacks the entire gentamicin gene cluster except the resistance gene *gmrA*. It appeared therefore that the enzyme catalyzing the terminal 6′-*N*-methylation step must be encoded by a gene outside the limits of the known cluster. Also, cell-free lysate of *M. echinospora* ΔBN was shown to carry out this conversion in the presence of SAM, and the enzymatic activity proved stable to initial fractionation using selective ammonium sulfate precipitation. We therefore contemplated searching for the elusive terminal methyltransferase by two parallel routes, one by conventional enzyme purification from *M. echinospora* and the other by bioinformatic analysis of genome sequence followed by the cloning and testing of plausible candidates. In the end, the genome-assisted approach proved quicker.

The whole-genome sequence of *M. echinospora* ATCC15835 was determined and assembled as described in [*Materials and Methods*](#s7){ref-type="sec"}. To identify candidate genes for the methylation at 6′-*N* of C1a and C2, we chose the protein sequences of two authentic aminoglycoside *N*-methyltransferases as probes. One of these was IstU, which is proposed to catalyze an analogous 6′-*N*-methylation step during biosynthesis of istamycin in *Streptomyces tenjimariensis* ([@r12], [@r16]). Four candidate genes---*orf0086*, *orf1678*, *orf12159*, and *orf3626* (GenBank accession nos. MF036116, MF036117, MF036132, and MF036133) with 40, 36, 38, and 27% protein sequence identities, respectively, to IstU ([*SI Appendix*, Table S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental))---were chosen, and each was inactivated in *M. echinospora* ATCC15835 through in-frame deletion. However, none of these mutants was found to abolish the methylation at 6′-*N*.

The second probe sequence chosen was GenN. In total, 19 candidate genes (GenBank accession nos. MF036118--MF036131 and MF036134--MF036138) were identified using the BLASTP program ([@r28]), with percentage sequence identities to GenN ranging from 26.67 to 40.35% ([*SI Appendix*, Table S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). Each candidate gene was cloned into expression vector pET28a(+) in *Escherichia coli*, and cell extracts were assayed for their ability to catalyze SAM-dependent conversion of C2 into C1, monitored by LC-ESI-HRMS ([*SI Appendix*, Fig. S6*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). The results showed that only the cell-free lysate of BL21(DE3)/pET28a(+)-*genL*(*orf5365*) transformed C2 to C1. No other candidate, including boiled BL21(DE3)/pET28a(+)-*genL*, catalyzed this conversion. The cell-free lysate of BL21(DE3)/pET28a(+)-*genL* also catalyzed the conversion of C1a to C2b significantly ([*SI Appendix*, Fig. S6*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)). These results strongly suggested that this enzyme, named GenL, is the elusive terminal methyltransferase catalyzing methylation on 6′-*N* of C1a and C2. The *genL* (GenBank accession no. MF036122) is separated from the known gentamicin biosynthetic cluster by 2.54 Mbp.

To confirm the function of *genL*, the gene was removed through in-frame deletion from the genome of *M. echinospora* ATCC15835. This mutant was verified through Southern blotting ([*SI Appendix*, Fig. S4 *A* and *B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) and then fermented, followed by LC-ESI-HRMS analysis of the extract. The results showed selective loss of the C1 and C2b components of the gentamicin C complex ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S4*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)), confirming that *genL* is the unique and essential gene catalyzing 6′-*N*-methylation on C2 and C1a in gentamicin biosynthesis. Complementation in trans with the wild-type *genL* gene ([*SI Appendix*, Fig. S5*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)) substantially restored C1 production (60% of wild type) and gave C2b levels 240% of wild type ([*SI Appendix*, Fig. S4*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)).

GenL Is Highly Specific for Terminal 6′-*N*-Methylation of C1a and C2. {#s5}
----------------------------------------------------------------------

Recombinant GenL was expressed as an N-terminally His~6~-tagged protein and purified from *E. coli* BLR cells as described in [*Materials and Methods*](#s7){ref-type="sec"}. After affinity purification on a Co^2+^-NTA column and gel-filtration chromatography on Sephadex S200, GenL was essentially homogenous as judged by SDS/PAGE and eluted as a single peak of protein with an estimated *M*~r~ of 43,000, roughly consistent with its being a dimer in solution (calculated *M*~r~ of the subunit 29,000). This purified enzyme preparation was active in the conversion of both C2 to C1 and of C1a to C2b ([Fig. 5 *A* and *B*](#fig05){ref-type="fig"}), as monitored by HPLC-MS, but was inactive against C2a, the C-6′ epimer of C2 ([Fig. 5*C*](#fig05){ref-type="fig"}).

![In vitro methyltransfer activities of GenL. In the presence of SAM, GenL converted gentamicin C1a (*A*) and C2 (*B*) to gentamicin C2b (*A*) and C1 (*B*), respectively, but had no effect on gentamicin C2a (*C*). The extracted ion traces on LC-MS of substrates are in gray and those of the products are in black. The Michaelis--Menten saturation curves of GenL-catalyzed methylations of C2 (*D*) and C1a (*E*) are also determined.](pnas.1711603115fig05){#fig05}

Kinetic analysis of the SAM-dependent methyltransferase activity of GenL was carried out with either C2 or C1a as substrate, using a continuous colorimetric assay based on enzymatically coupling the production of *S*-adenosylhomocysteine (SAH) to a change in absorbance at 510 nm ([@r29], [@r30]). The data were fitted to the integrated form of the Michaelis--Menten equation. For C2, *k*~cat~ was 0.043·s^−1^, and *K*~m~ was 77.8 ± 8 µM; while for C1a, *k*~cat~ was 0.040·s^−1^, and *K*~m~ was 346.8 ± 86 µM ([Fig. 5 *D* and *E*](#fig05){ref-type="fig"}). The same assay was also used to screen several other pathway intermediates (C2a, G418, JI-20A, and JI-20B) ([@r20]), and other gentamicin-related aminoglycosides, including sisomicin, kanamycin A, kanamycin B, and tobramycin. All of these were found to be essentially inactive as substrates for GenL, except for a slow reaction with sisomicin.

Discussion {#s6}
==========

Methylation is an important reaction in the biosynthesis of specialized metabolites in both plants and microorganisms, where it contributes significantly to the chemical diversity of the products ([@r31], [@r32]). The results presented here significantly advance our understanding of the way in which methylation shapes the branched biosynthetic pathway to the gentamicin C complex, an established drug used to combat serious infections. These insights are key to the success of efforts to redirect the course of biosynthesis toward specific components of the complex and give an appreciation of the scope for altering the methylation pattern on the gentamicin pseudotrisaccharide scaffold to generate various metabolites for testing as antibiotics or for other therapeutic indications ([@r3]). Methyltransferases involved in the biosynthesis of natural products have considerable potential for the engineering of new derivatives ([@r33][@r34]--[@r35]). There is renewed interest in aminoglycoside antibiotics ([@r3], [@r36]) driven in part by the increasing incidence of pathogenic strains resistant to many other antibiotics but also by encouraging evidence that toxicity and vulnerability to resistance mechanisms can be ameliorated by semisynthesis ([@r37]). For example, etimicin is prepared from gentamicin C1a ([@r38]) and plazomicin (currently in phase III trials) from the gentamicin-like sisomicin ([@r39]). If the single components of the gentamicin C complex can be efficiently prepared by low-cost direct fermentation, it will widen the scope for such efforts.

In previous work, three consecutive methylation steps in the later stages of gentamicin biosynthesis have been firmly established as being catalyzed, respectively, by the 3′′-*N*-methyltransferase GenN, the 4″-*C*-methyltransferase GenD1, and the 6′-*C*-methyltransferase GenK ([@r19], [@r20], [@r28]). However, here we have shown that the three methylations may take place in an alternative order, giving rise to a form of network. A commercial batch of gentamicin C has been shown to contain as trace contaminants gentamicins lacking one or more of these methyl groups ([@r27]), and specific deletion of *genN* has been shown, for example, to increase the yield of several 3′′-*N*-desmethylgentamicins ([@r19], [@r28]). To explore this further, we therefore constructed the complete combinatorial set of seven mutants in which one, two, or all three of methyltransferase genes had been independently deleted in-frame. LC-ESI-HRMS analysis of these mutants gave indications of the substrate flexibility of these enzymes.

First, the ΔgenD1ΔgenKΔgenN mutant produced no intermediate more advanced than **2**, which confirms that no other methyltransferase present in *M. echinospora* can methylate this molecule. Also as expected, in ΔgenD1ΔgenK, ΔgenNΔgenK, and ΔgenD1ΔgenN, **3**, **6**, and **7**, respectively, were seen. In the ΔGenK mutant, GenN clearly out-competes GenD1 because the products are those of the normal pathway: **3** and **4**. In the ΔgenD1 mutant, GenK and GenN collaborate to produce doubly methylated **9** via either **3** or **7**, while in the ΔgenN mutant, GenK and GenD1 collaborate to produce doubly labeled **10** via either **6** or **7**.

Purification of the intermediates accumulated in these mutants also provided a panel of gentamicin metabolites. Further insight into methyltransferase substrate specificity was gained by feeding these individual metabolites to strains of *M. echinospora* stripped of the resident gentamicin biosynthetic gene cluster, except for a resistance gene and *genN*, *genD1*, or *genK*. The results showed that GenK and GenD1 are somewhat more versatile than GenN in accepting alternative substrates ([Fig. 3](#fig03){ref-type="fig"}). Even so, **6** is not a substrate for either GenK or GenN, so **10** must be formed via **7**, and since **10** is not a substrate for GenN, neither **6** nor **10** are competent intermediates in biosynthesis of the gentamicin C complex. Thus, the only minor alternative pathways that can contribute to production of the gentamicin C complex lead from **3** to **9** to **5**, inverting the normal order in which GenD1 and GenK act, or from **2** to **7** to **9** to **5**, if GenK acts before GenN and GenD1 ([Fig. 1](#fig01){ref-type="fig"}). Agar diffusion assays against *Bacillus pumilis* showed that, with the important exception of the natural intermediate X2, derivatives tested that lacked any of the core methylations of the gentamicin C complex were essentially inactive ([*SI Appendix*, Fig. S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental)), emphasizing the importance of both the pattern and the extent of this modification for antibiotic activity. The relatively tight selectivity of the three methyltransferases rationalizes why the conventional pathway dominates in the wild type. Although these results provide proof of concept for directing biosynthesis toward gentamicin-related metabolites with altered methylation patterns, enzyme engineering to modify substrate specificity would be required to make this an efficient process, and further modification of those templates would be required to restore antibiotic activity.

The biosynthetic genes for all aminoglycoside antibiotics so far studied are found clustered together on the genome, and this has greatly facilitated their analysis ([@r13], [@r17]). A surprising feature of the gentamicin biosynthesis in *M. echinospora* is that the methyltransferase gene *genL*, which we have shown here is essential to catalyze the terminal methylations, is located 2.54 Mbp away from the known biosynthetic gene cluster. This was previously annotated as an orphan methyltransferase, along with many other similar genes in *M. echinospora*, and it is not located near any recognizable genes of specialized metabolism. The dependence of a biosynthetic gene cluster on the collaboration of a remotely located gene is not unprecedented ([@r40]), and its discovery here demonstrates the power of a genome-driven approach to uncover such "missing" elements of a biosynthetic pathway. Whether GenL also catalyzes a different reaction in primary or specialized metabolism is unknown. We have characterized recombinant GenL as a homodimeric SAM-dependent enzyme with exactly the expected substrate specificity. GenL showed no activity against earlier intermediates in the pathway. GenL bears very limited sequence similarity to the 3′′-*N*-methyltransferase GenN, and it would be of considerable interest to compare the crystal structures, substrate ranges, and reaction mechanisms of these two enzymes.

The separation of gentamicin C components has previously been at least partially achieved by chemical derivatization, column chromatography, and deprotection ([@r8]). The present work shows the feasibility, with the identity and role of every methyltransferase established, of achieving the same goal more conveniently by direct fermentation of an appropriately engineered mutant strain. Given the growing global threat of antibiotic resistance, it is of pressing importance to maximize the potential of the existing arsenal of antibacterial compounds, as well as to seek new targets. The results that we have obtained should encourage the use of individual congeners as starting points for semisynthesis to create novel aminoglycosides, Also, the reportedly lower toxicity of certain components of the gentamicin C complex ([@r6], [@r7]) deserves to be fully and critically evaluated, and the present work brings this prospect closer.

Materials and Methods {#s7}
=====================

Methods describing gene cloning, gene deletion and complementation, fermentation of strains and feeding experiments, LC-ESI-HRMS analyses, isolation and characterization of compounds, genome sequencing, cell-free assay, protein overexpression and purification, enzymatic assay, and kinetic characterization are described in detail in [*SI Appendix*, *SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1711603115/-/DCSupplemental).
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